28/4/24, 6:58 Assessment of Cardiovascular Disease Risk: A 2022 Update - PubMed

An official website of the United States government

Here's how you know

full text links

Review Endocrinol Metab Clin North Am. 2022 Sep;51(3):483-509.

doi: 10.1016/j.ecl.2022.02.005. Epub 2022 Jul 4.

Assessment of Cardiovascular Disease Risk: A 2022

Update
Earl Goldsborough 3rd 1 , Ngozi Osuji 2 , Michael J Blaha 3

Affiliations
PMID: 35963625 DOI: 10.1016/j.ecl.2022.02.005

Abstract
Assessment of atherosclerotic cardiovascular disease (ASCVD) risk is the cornerstone of primary
ASCVD prevention, enabling targeted use of the most aggressive therapies in those most likely to
benefit, while guiding a conservative approach in those who are low risk. ASCVD risk assessment
begins with the use of a traditional 10-year risk calculator, with further refinement through the
consideration of risk-enhancing factors (particularly lipoprotein(a)) and subclinical atherosclerosis
testing (particularly coronary artery calcium (CAC) testing). In this review, we summarize the current
field of ASCVD risk assessment in primary prevention and highlight new guidelines from the
Endocrine Society.

Keywords: Atherosclerosis; Cardiovascular disease; Cardiovascular risk; Coronary artery calcium;

Family history; Lipoprotein(a); Primary prevention; Risk assessment.

Copyright © 2022 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Related information
MedGen

LinkOut - more resources

Full Text Sources
Elsevier Science
W.B. Saunders
Medical
MedlinePlus Health Information

https://pubmed.ncbi.nlm.nih.gov/35963625/ 1/1